Energy & climate · Pipeline & development
Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026
VENTURE Analysis Finds 74% of Participants Receiving Subcutaneous VK2735 Improved by at Least One BMI Category after 13 Weeks VK2735 Treatment Led to Improvement Across Multiple Cardiometabolic Markers SAN DIEGO, Nov. 15, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:...
Original source
Read the source — prnewswire.com ↗We link to the original publisher. The summary above is a short guide; read the original for the full details.